robalzotan and Migraine-Disorders

robalzotan has been researched along with Migraine-Disorders* in 1 studies

Other Studies

1 other study(ies) available for robalzotan and Migraine-Disorders

Article	Year
Robalzotan AstraZeneca. Current opinion in investigational drugs (London, England : 2000), 2000, Volume: 1, Issue:2 AstraZeneca (formerly Astra) is developing robalzotan, a 5-HT1A antagonist, for the potential treatment of depression and anxiety. The compound has entered phase II trials, and NDA and MAA filings are expected after 2003 [352095,377656]. In August 2000, Lehman Brothers predicted that the compound had a 20% probability of reaching the market, with a predicted launch date of 2005 [384880]. Topics: Animals; Anti-Anxiety Agents; Anxiety; Benzopyrans; Drugs, Investigational; Humans; Migraine Disorders; Patents as Topic; Serotonin Antagonists; Structure-Activity Relationship	2000

Article

Year

Current opinion in investigational drugs (London, England : 2000), 2000, Volume: 1, Issue:2

AstraZeneca (formerly Astra) is developing robalzotan, a 5-HT1A antagonist, for the potential treatment of depression and anxiety. The compound has entered phase II trials, and NDA and MAA filings are expected after 2003 [352095,377656]. In August 2000, Lehman Brothers predicted that the compound had a 20% probability of reaching the market, with a predicted launch date of 2005 [384880].

Topics: Animals; Anti-Anxiety Agents; Anxiety; Benzopyrans; Drugs, Investigational; Humans; Migraine Disorders; Patents as Topic; Serotonin Antagonists; Structure-Activity Relationship

2000